Psilocybin Works in the Lab. Can It Survive the Clinic?

Despite FDA guidance released in July 2026 advancing psychedelic drug trials, key therapeutic context elements like therapist training and session environment lack regulatory standardisation, risking inconsistent clinical outcomes for psilocybin-assisted therapy. The NHS experience highlights operational challenges and workforce strains, while states like Oregon and Colorado create new licensing frameworks absent at the federal and UK regulator level.

This Wire brief sits within Fusion42's coverage of Health: Mental Health.